Skip to main content
SpringerLink
Log in

Pharmacokinetics of valproate in pregnancy: Mother-foetus-newborn

  • Published:
Pharmaceutisch Weekblad Aims and scope Submit manuscript

Abstract

An increased risk of seizures during and immediately after labour has been observed in epileptic women, and it is recognized that serum levels of antiepileptic drugs may decrease in pregnancy. Several studies have suggested that total valproate levels fall, but that free fractions increase during pregnancy. Recent findings suggest that the actual metabolism of valproate is not altered by pregnancy and that the changes of the plasma clearance are due primarily to decreased protein binding. The levels of free drug will not change significantly as pregnancy advances. However, dose reduction after delivery may be necessary to avoid toxicity. Valproate and its metabolites undergo placental transfer. In the foetus the plasma level of valproate and the protein binding are higher than in maternal plasma, and the halflife of valproate following placental transfer is considerably longer than in adults. Only small amounts of valproate appear in breast milk and those are not likely to cause any problems. During pregnancy and the first month after delivery preferably both total and free valproate serum levels should be closely monitored to determine the lowest effective dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schmidt D, Beck-Mannagetta G, Janz D, Koch S. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt D, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:39–49.

    Google Scholar 

  2. Yerby M. Problems and management of the pregnant woman with epilepsy. Epilepsia 1987;28 Suppl 3:S29–37.

    PubMed  Google Scholar 

  3. Philbert A, Dam M. Antiepileptic drug disposition during pregnancy: review of the litterature. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt D, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:109–14.

    Google Scholar 

  4. Levy RH, Yerby MS. Effects of pregnancy on antiepileptic drug utilization. Epilepsia 1985;26 Suppl 1:S52–7.

    PubMed  Google Scholar 

  5. Robert E. Valproic acid and spina bifida: a preliminary report — France. MMRR 1982;31:565–6.

    Google Scholar 

  6. Bourgeois B, Beaumanoir A, Blajev B, De la Cruz N, Despland PA, Egli M, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28 Suppl 2:S8–11.

    PubMed  Google Scholar 

  7. Nau H, Kuhnz W, Egger H-J, Rating D, Helge H. Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982;7:508–43.

    PubMed  Google Scholar 

  8. Krauer B, Krauer F. Drug kinetics in pregnancy. In: Gibaldi M, Prescott L, eds. Handbook of clinical pharmacokinetics. Balgowlah: Adis Press, 1983:1–17.

    Google Scholar 

  9. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid — 1988. Clin Pharmacokinet 1988;15:367–89.

    PubMed  Google Scholar 

  10. Sabers A, Dam M. Pregnancy, delivery, and puerperium. In: Dam M, Gram L, eds. Comprehensive epileptology. New York: Raven Press, 1991:299–307.

    Google Scholar 

  11. Leppik IE. Pharmacokinetics of antiepileptic drugs during pregnancy. Semin Neurol 1988;8(3):240–6.

    PubMed  Google Scholar 

  12. Wittfodt W, Nau H, Rating D, Helge H.13C-labeled valproic acid pulse dosing during steady state antiepileptic therapy for pharmacokinetic studies during pregnancy. In: Schmidt HL, Förstel H, Heinzinger K, eds. Stable isotopes. Amsterdam: Elsevier, 1982:265–70.

    Google Scholar 

  13. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990; 18(1):20–36.

    PubMed  Google Scholar 

  14. Nau H, Schmidt-Gollwitzer M, Kuhnz W, Koch S, Helge H, Rating D. Antiepileptic disposition, protein binding, and estradiol/progesterone serum concentration ratios during pregnancy. In: Porter R, Mattson R, Ward A, Dam M, eds. Advances in epileptology. New York: Raven Press, 1984:239–49.

    Google Scholar 

  15. Riva R, Albani F, Contin M, Baruzzi A, Altomare M, Merlini GP, et al. Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid. Ther Drug Monit 1984;6:25–30.

    PubMed  Google Scholar 

  16. Patel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia 1979;20:85–90.

    PubMed  Google Scholar 

  17. Hunter J. Enzyme induction and inhibition in human pregnancy. In: Richens A, Woodford FP, eds. Anticonvulsant drugs and enzyme induction. Amsterdam: Elsevier, 1976:131–3.

    Google Scholar 

  18. Nau H, Löscher W. Valproic acid and metabolites. Pharmacological and toxicological studies. Epilepsia 1984;25 Suppl 1:S14–22.

    PubMed  Google Scholar 

  19. Schobben F, Van der Kleijn E, Gabreels PJM. Pharmacokinetics of di-N-propylacetate in epileptic patients. Eur J Clin Pharmacol 1975;8:97–105.

    Article  PubMed  Google Scholar 

  20. Sackellares C, Sato S, Dreifuss FE, Penry JK. Reduction of steady-state valproate levels by other antiepileptic drugs. Epilepsia 1981;22:437–41.

    PubMed  Google Scholar 

  21. Oxley J, Hedges A, Makki KA, Monks A, Richens A. Lack of enzyme inducing effects of sodium valproate. Br J Clin Pharmacol 1979;8:189–90.

    PubMed  Google Scholar 

  22. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate. A five-year follow-up study of 100 children with epilepsy. Acta Neurol Scand 1982;65:504–23.

    PubMed  Google Scholar 

  23. Philbert A, Dam M. The epileptic mother and her child. Epilepsia 1982;23:85–99.

    PubMed  Google Scholar 

  24. Nau H, Helge H, Luck W. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. J Pediatr 1984;104:627–34.

    PubMed  Google Scholar 

  25. Koerner M, Yerby M, Friel P, McCormick K. Valproic acid disposition and protein binding in pregnancy. Ther Drug Monit 1989;11:228–30.

    PubMed  Google Scholar 

  26. Bardy AH, Hiilesmaa VK, Teramo K, Neuvonen PJ. Protein binding of antiepileptic drugs during pregnancy, labor, and puerperium. Ther Drug Monit 1990;12:40–6.

    PubMed  Google Scholar 

  27. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988;14:217–40.

    PubMed  Google Scholar 

  28. Knott C, Reynolds F. Therapeutic drug monitoring in pregnancy. Rationale and current status. Clin Pharmacokinet 1990;19(6):425–33.

    PubMed  Google Scholar 

  29. Choonara IA, Rane A. Therapeutic drug monitoring of anticonvulsants. State of art. Clin Pharmacokinet 1990;18(4):318–28.

    PubMed  Google Scholar 

  30. Cramer JA, Matsson RH. Valproic acid:in vitro plasma protein binding and interaction with phenytoin. Ther Drug Monit 1979;23:307–13.

    Google Scholar 

  31. Levy RH, Bowdle TA, Patel IH, Wilensky AJ. Variability in valproate binding and clearance: implications in therapeutic monitoring. Epilepsia 1981;22:240–1.

    Google Scholar 

  32. Levy RH. Monitoring of free valproic acid levels? Ther Drug Monit 1980;2:199–201.

    PubMed  Google Scholar 

  33. Farrell K, Abbott FS, Orr JM, Applegarth A, Jan JE, Wong PK. Free and total serum valproate concentrations: their relationship to seizure control, liver enzymes and plasma ammonia in children. Can J Neurol Sci 1986;13:252–5.

    PubMed  Google Scholar 

  34. Kilpatrick CJ, Fullinfaw RO, Burg RW, Moulds RFW. Plasma concentrations of unbound valproate and management of epilepsy. Aust NZ J Med 1987;17:574–7.

    Google Scholar 

  35. Barre J, Didey F, Delion F, Tillement J-P. Problems in therapeutic monitoring. Free drug level monitoring. Ther Drug Monitor 1988;10:133–43.

    Google Scholar 

  36. Johannessen SI, Løyning Y, Munthe-Kaas AW. IX. Medical treatment. General aspects. In: Dam M, Gram L, eds. Comprehensive epileptology. New York: Raven Press, 1991:505–24.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The National Centre for Epilepsy, N-1301, Sandvika, Norway

    Svein I. Johannessen

Authors
  1. Svein I. Johannessen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johannessen, S.I. Pharmacokinetics of valproate in pregnancy: Mother-foetus-newborn. Pharmaceutisch Weekblad Scientific Edition 14, 114–117 (1992). https://doi.org/10.1007/BF01962699

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01962699

Keywords

Search

Navigation